TG Therapeutics (TGTX) Projects $616 Million Revenue in 2025, Exceeding Analyst Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Source: stocktwits
- Optimistic Revenue Outlook: TG Therapeutics anticipates global revenue of $616 million in 2025, surpassing the analysts' consensus estimate of $606 million, indicating strong market performance and growth potential.
- Quarterly Revenue Projections: The U.S. net product revenue for BRIUMVI is expected to reach approximately $182 million in Q4 2025, reflecting the product's increasing acceptance and sales capability in the market.
- Positive Stock Market Reaction: TG Therapeutics' stock rallied 9% in Wednesday's premarket, demonstrating strong investor confidence in the company's future revenue outlook, with retail chatter on Stocktwits increasing by 195%.
- Future Milestones: The company plans to release pivotal data from the ENHANCE trial by mid-2026, further enhancing BRIUMVI's market recognition and sales growth, showcasing ongoing investment and strategic positioning in R&D.
Analyst Views on TGTX
Wall Street analysts forecast TGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TGTX is 43.50 USD with a low forecast of 15.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 30.680
Low
15.00
Averages
43.50
High
60.00
Current: 30.680
Low
15.00
Averages
43.50
High
60.00
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
